(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...
The Massachusetts Health Policy Commission doesn’t have the authority to prevent the partnership from going through, but it ...
CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...
Udolf Properties, a privately held real estate firm, said Wednesday it has acquired a CVS-anchored commercial building on ...
CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the pharmacy benefit manager Caremark, will not add Yeztugo, Gilead’s (NASDAQ:GILD) newly approved HIV PrEP, to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results